Literature DB >> 3263884

In vivo catabolism of alpha 1-antichymotrypsin is mediated by the Serpin receptor which binds alpha 1-proteinase inhibitor, antithrombin III and heparin cofactor II.

S V Pizzo1, A E Mast, S R Feldman, G Salvesen.   

Abstract

The in vivo catabolism of 125I-labeled alpha 1-antichymotrypsin was studied in our previously described mouse model. Native alpha 1-antichymotrypsin cleared with an apparent t1/2 of 85 min, but alpha 1-antichymotrypsin in complex with chymotrypsin or cathepsin G cleared with a t1/2 of 12 min. Clearance of the complex was blocked by a large molar excess of unlabeled complexes of proteinases with either alpha 1-antichymotrypsin or alpha 1-proteinase inhibitor. These studies indicate that the clearance of alpha 1-antichymotrypsin-proteinase complexes utilizes the same pathway as complexes with the homologous inhibitor alpha 1-proteinase inhibitor. Previous studies have demonstrated that this pathway is also responsible for the catabolism of two other serine proteinase inhibitors, antithrombin III and heparin cofactor II. This pathway is thus responsible for removing several proteinases involved in coagulation and inflammation from the circulation, thereby decreasing the likelihood of adventitious proteolysis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263884     DOI: 10.1016/0304-4165(88)90005-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.

Authors:  David Ulmert; Andrew J Vickers; Howard I Scher; Charlotte Becker; Peter Iversen; David Frankel; Jens-Kristian Jensen; Tine Kold Olesen; Hans Lilja
Journal:  Clin Chem Lab Med       Date:  2012-11       Impact factor: 3.694

2.  Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes.

Authors:  D H Perlmutter; G I Glover; M Rivetna; C S Schasteen; R J Fallon
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

3.  Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.

Authors:  Susan Evans-Axelsson; David Ulmert; Anders Örbom; Pernilla Peterson; Olle Nilsson; Johan Wennerberg; Joanna Strand; Karin Wingårdh; Tomas Olsson; Zandra Hagman; Vladimir Tolmachev; Anders Bjartell; Hans Lilja; Sven-Erik Strand
Journal:  Cancer Biother Radiopharm       Date:  2012-04-10       Impact factor: 3.099

Review 4.  C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.

Authors:  C E Hack; A C Ogilvie; B Eisele; A J Eerenberg; J Wagstaff; L G Thijs
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

5.  Potential clinical importance of the activation peptide of prostate-specific antigen.

Authors:  Laura M Voeghtly; Ida B Thøgersen; Zuzana Valnickova; Kristian W Sanggaard; Charleen T Chu; Tim D Oury; Jan J Enghild
Journal:  Int J Clin Exp Pathol       Date:  2009-06-20

6.  Acute phase protein response and polymorphonuclear leukocyte cathepsin g release after slow interleukin-1 stimulation in the rat.

Authors:  P Björk; T Gudmundsson; K Ohlsson
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

7.  Plasma Proteolytic Cascade Activation during Neonatal Cardiopulmonary Bypass Surgery.

Authors:  Susan A Maroney; Julie A Peterson; Wes Zwifelhofer; Nicholas D Martinez; Ke Yan; Rachel S Bercovitz; Ronald K Woods; Alan E Mast
Journal:  Thromb Haemost       Date:  2018-08-07       Impact factor: 5.249

8.  Differential Proliferative Characteristics of Alveolar Fibroblasts in Interstitial Lung Diseases: Regulative Role of IL-1 and PGE(2).

Authors:  E Fireman; S Ben Efraim; J Greif; H Peretz; S Kivity; M Topilsky; Y Rodrig; A Yellin; R N Apte
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.